PALATIN TECHS DL-01
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more
PALATIN TECHS DL-01 (PTN) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PALATIN TECHS DL-01 (PTN) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PALATIN TECHS DL-01 - Net Assets Trend (None–None)
This chart illustrates how PALATIN TECHS DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PALATIN TECHS DL-01 (None–None)
The table below shows the annual net assets of PALATIN TECHS DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PALATIN TECHS DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PALATIN TECHS DL-01 Competitors by Market Cap
The table below lists competitors of PALATIN TECHS DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Focus Universal Inc
NASDAQ:FCUV
|
$2.02 Million |
|
Vectus Biosystems Ltd
AU:VBS
|
$2.02 Million |
|
NorCom Information Technology GmbH & Co. KGaA
XETRA:NC5A
|
$2.02 Million |
|
Megalestari Epack Sentosaraya Pt
JK:EPAC
|
$2.02 Million |
|
Traka Resources Ltd
AU:TKL
|
$2.02 Million |
|
MMEX Resources Corp
PINK:MMEX
|
$2.02 Million |
|
DB Energy S.A.
WAR:DBE
|
$2.02 Million |
|
Federal International Holdings Bhd
KLSE:8605
|
$2.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PALATIN TECHS DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PALATIN TECHS DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PALATIN TECHS DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PALATIN TECHS DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PALATIN TECHS DL-01 (PTN) | €- | N/A | N/A | $2.02 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |